Trastuzumab-induced cardiac dysfunction: A 'dual-hit'

Experimental and Clinical Cardiology

Volumn 16, Issue 3, 2011, Pages 70-74

  Zeglinski, Matthew ^a   Ludke, Ana ^a   Jassal, Davinder S ^a,b,c   Singal, Pawan K ^a  

^a ST BONIFACE GENERAL HOSPITAL   (Canada)

^b Section of Cardiology   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Doxorubicin; Epidermal growth factor; Heart failure; Oxidative stress; Renin angiotensin system

Indexed keywords

ACLARUBICIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; IDARUBICIN; NEU DIFFERENTIATION FACTOR; PROBUCOL; RAZOXANE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRASTUZUMAB;

ADJUVANT THERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DAMAGE; DRUG INDUCED DISEASE; HEART DISEASE; HEART FAILURE; HEART MUSCLE CELL; HUMAN; OXIDATIVE STRESS; REVIEW;

EID: 80054886881     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Canadian Cancer Society/Steering Committee on Canadian Cancer Statistics, Toronto, Ontario, 2011.
2. Jassal DS, Han SY, Hans C, et al. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. J Am Soc Echocardiogr 2009;22:418-24.
3. Canadian Medical Association. Clinical practice guidelines for the care and treatment of breast cancer. CMAJ 2011. (In press)
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82. (Pubitemid 17231334)
5. Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol 2001;28:4-11. (Pubitemid 33065104)
6. Nahta R, Esteva FJ. Herceptin: Mechanisms of action and resistance. Cancer Lett 2006;232:123-8.
7. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000;19:6115-21. (Pubitemid 32059461)
8. Piccart-Gebhart MJ, Procter M, Leylan-Jones B, et al. Trastuzumab after the adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72. (Pubitemid 41464705)
9. Wadhwa D, Fallah-Rad N, Grenier D, et al. Trastuzumab mediated cardiotoxicity in the setting of the adjuvant chemotherapy for breast cancer: A retrospective study. Breast Cancer Res Treat 2009;117:357-64.
10. Gutierrez C, Schiff R. HER2: Biology, detection, and clinical implications. Arch Pathol Lab Med 2011;135:55-62.
11. Guarneri Jain KK, Casper ES, Geller NL, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985;3:818-26. (Pubitemid 15062910)
12. Tsang W, Moe G. Trastuzumab and heart failure. Cardiol Rounds 2007;8:1-6.
13. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: What the cardiologist needs to know. Nat Rev Cardiol 2010;7:564-75.
14. Grazette LP, Boecker W, Matsui T, et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: Implications for herceptin-induced cardiomyopathy. JACC 2004;44:2231-8. (Pubitemid 39576044)
15. Walker JR, Sharma A, Lytwyn M, et al. The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity. J Am Soc Echocardio 2011;6:699-705.
16. Nakagami H, Takemoto M, Liao JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardio 2003;35:851-9. (Pubitemid 36773597)
17. Cardinale D, Colombo A, Maria T, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-81. (Pubitemid 44901520)
18. Siveski-Iliskovic N, Kaul N, Singal PK. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circ 1994;89:2829-35. (Pubitemid 24173705)
19. Li T, Danelisen I, Bello-Klein A, Singal PK. Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc Res 2000;46:523-30. (Pubitemid 30319337)
20. Kumar D, Kirshenbaum LA, Li T, Danelisen I, Singal PK. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxidant Redox Signal 2001;3:135-45. (Pubitemid 32240636)
21. Weiss RB. The anthracyclines: Will we ever find a better doxorubicin? Sem Onco 1992;19:670-86. (Pubitemid 23004844)
22. Ludke ARL, Al-Shudiefat AAR, Dhingra S, Jassal DS, Singal PK. A consise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity. Can J Physiol Pharmacol 2009;87:756-63.
23. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: Pathophysiology and prevention. FASEB 1997;11:931-6. (Pubitemid 27425894)
24. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14.
25. Zhao W, Ahokas RA, Weber KT, Sun Y. ANG II-induced cardiac molecular and cellular events: Role of aldosterone. Am J Physiol Heart Circ Physiol 2006;291:H336-H343.
26. Walker JR, Singal PK, Jassal DS. The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure. Exp Clin Cardiol 2009;14:e62-e67.
27. Weiss RB, Sarosy G, Clagett-Carr K, Russo M, Leyland-Jones B. Anthracycline analogs: The past, present, and future. Can Chemo Pharmacol 1986;18:185-97. (Pubitemid 17007730)
28. Muggia FM, Green MD. New antracycline antitumor antibiotics. Clin Rev Onco/Hema 1991;11:43-64.
29. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced heart failure: Mechanism and modulation. Mol Cell Biochem 2000;207:77-85. (Pubitemid 30399372)
30. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharm Rev 2004;56:185-229. (Pubitemid 38720829)
31. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-41. (Pubitemid 29094544)
32. Cvetkovic RS, Scott LJ. Dexrazoxane: A review of its use for cardioprotection during anthracycline chemotherapy. Drugs 2005;65:1005-24. (Pubitemid 40667518)
33. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricle dysfunction: The CAPRICORN randomized trial. Lancet 2001;325:1385-90. (Pubitemid 32455364)
34. Iliskovic N, Hasinoff BB, Malisza KL, Li T, Danelisen I, Singal PK. Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy. Mol Cell Biochem 1999;196:43-9. (Pubitemid 29338777)
35. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circ 1995;91:10-5.
36. Landgraf R. HER2 (ERBB2): Functional diversity from structurally conserved building blocks. Breast Can Res 1997;9:202-12.
37. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the herceptin fab. Nature 2003;421:756-60. (Pubitemid 36227628)
38. Worthylake R, Wiley HS. Structural aspects of the epidermal growth factor receptor required for transmodulation of erbB-2/neu. J Bio Chem 1997;272:8594-601. (Pubitemid 27147825)
39. Yarden Y, Sliwkowski MX. Untangelling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-37.
40. Negro A, Brar B, Lee KF. Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 2004;59:1-12. (Pubitemid 41327144)
41. Guglin M, Cutro R, Mishkin JD. Trastuzumab-induced cardiomyopathy. J Cardiac Fail 2008;14:437-44. (Pubitemid 351749842)
42. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84. (Pubitemid 41464706)
43. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-65. (Pubitemid 34546747)
44. Jiang Z, Zhou M. Neurgulin signaling and heart failure. Curr Heart Fail Rep 2010;7:42-7.
45. Negro A, Brar BK, Gu Y, Petersin KL, Vale W, Lee KF. erbB2 is required for G protein-coupled receptor signaling in the heart. PNAS 2006;103:15889-93. (Pubitemid 44657562)
46. Pentassuglia L, Sawyer DB. The role of neuregulin-1β/ErbB signaling in the heart. Exper Cell Res 2009;315:627-37.
47. Peng X, Guo X, Borkan SC, et al. Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes. J Biol Chem 2005;13:13148-52.
48. Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 2006;41:228-35. (Pubitemid 44080212)
49. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibril disarray in rat ventricular myocytes by neuregulin-1β and Anti-erbB2: Potential mechanism for trastuzumab-induced cardiomyopathy. Circulation 2002;105:1551-4. (Pubitemid 34297631)
50. Gordon LI, Burke MA, Singh AT, et al. Blockade of the erbB2 receptor induced cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 2009;284:2080-7.
51. Walker JR, Bhullar N, Fallah-Rad N, et al. Role of three-dimensional echocardiography in breast cancer: Comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 2010;28:3429-36.
52. Lemarie CA, Paradise P, Schiffrin EL. New insights on signaling cascades induced by cross talk between ANG II and aldosterone. J Mol Med 2008;86:449-56.
53. Lou H, Kaur K, Sharma A, Singal PK. Adriamycin-induced oxidative stress, activation of MAP kinases and apoptosis in isolated cardiomyocytes. Pathophysiol 2006;13:103-9.
54. Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. JACC 2011;57:2263-70.
55. Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J 2009;158:294-301.
56. Ho E, Brown A, Barrett P, et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: A speckle tracking echocardiographic study. Heart 2010;96:701-7.
57. Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011;107:1375-80.